229 related articles for article (PubMed ID: 30413320)
1. Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma.
Subramanian C; Cohen MS
Surgery; 2019 Jan; 165(1):202-210. PubMed ID: 30413320
[TBL] [Abstract][Full Text] [Related]
2. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics.
Subramanian C; Cohen MS
Surgery; 2022 Jan; 171(1):119-129. PubMed ID: 34353633
[TBL] [Abstract][Full Text] [Related]
4. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
5. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.
Buishand FO; Liu-Chittenden Y; Fan Y; Tirosh A; Gara SK; Patel D; Meerzaman D; Kebebew E
Surgery; 2020 Jan; 167(1):224-232. PubMed ID: 31522749
[TBL] [Abstract][Full Text] [Related]
6. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
8. Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Yang Z; Cheng H; Zhang Y; Zhou Y
Med Sci Monit; 2021 Mar; 27():e928523. PubMed ID: 33667214
[TBL] [Abstract][Full Text] [Related]
9. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.
Liang W; Sun F
Front Endocrinol (Lausanne); 2021; 12():538364. PubMed ID: 33776902
[TBL] [Abstract][Full Text] [Related]
11. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract][Full Text] [Related]
12. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
Surgery; 2022 Jan; 171(1):111-118. PubMed ID: 34261605
[TBL] [Abstract][Full Text] [Related]
13. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
14. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
15. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
16. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
[TBL] [Abstract][Full Text] [Related]
17. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
18. Identification of important invasion and proliferation related genes in adrenocortical carcinoma.
Alshabi AM; Vastrad B; Shaikh IA; Vastrad C
Med Oncol; 2019 Jul; 36(9):73. PubMed ID: 31321566
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
20. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.
Dos Santos Passaia B; Lima K; Kremer JL; da Conceição BB; de Paula Mariani BM; da Silva JCL; Zerbini MCN; Fragoso MCBV; Machado-Neto JA; Lotfi CFP
Invest New Drugs; 2020 Jun; 38(3):899-908. PubMed ID: 31441020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
